tbuckley/cabot-search huggingface dataset:
Quality of Care in Patients with Diabetes
Journal: Annals of Internal Medicine (2002)

Letters2 July 2002Quality of Care in Patients with DiabetesThe EditorsThe EditorsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-1-200207020-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. Cobin and Rodbard expressed disappointment in the Summary for Patients (1) that accompanied Greenfield and colleagues' article (2). The Editors respectfully disagree with their assertions that the summary uncritically accepted the paper's conclusions, extrapolated to physicians' practices in general, and oversimplified facts. Contrary to our correspondents' view, the summary drew no conclusions about which type of physicians provide the best diabetes care. Rather, it concluded that without analyses that consider patient factors and physician-level clustering, one might come to erroneous conclusions about the care provided by different types of doctors. The summary did not overgeneralize but clearly ...References1. . Summaries for patients. Comparing the quality of diabetes care by generalists and specialists. Ann Intern Med. 2002;136:I42. [PMID: 11928735] LinkGoogle Scholar2. Greenfield S, Kaplan SH, Kahn R, Ninomiya J, Griffith JL. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. Ann Intern Med. 2002;136:111-21. [PMID: 11790062] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProfiling Care Provided by Different Groups of Physicians: Effects of Patient Case-Mix (Bias) and Physician-Level Clustering on Quality Assessment Results Sheldon Greenfield , Sherrie H. Kaplan , Richard Kahn , John Ninomiya , and John L. Griffith Quality of Care in Patients with Diabetes Parthiv J. Mahadevia , Seth Himelhoch , and Joel Braunstein Quality of Care in Patients with Diabetes Rhoda H. Cobin and Helena W. Rodbard Quality of Care in Patients with Diabetes Sam Weir , Robert Stone , Philip Levy , Stephen F. Hodgson , and Barbara Fleming Quality of Care in Patients with Diabetes Sheldon Greenfield , Sherrie H. Kaplan , and Richard Kahn Metrics 2 July 2002Volume 137, Issue 1Page: 72KeywordsFactor analysisHealth care qualityPatients ePublished: 2 July 2002 Issue Published: 2 July 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Mass spectrometric analysis of tobacco-specific hemoglobin adducts
Authors: G Schäffler, C Betz, E Richter
Journal: Environmental Health Perspectives (1993)

Hemoglobin adducts of the common metabolite of the tobacco-specific nitrosamine (ISNA) 4-hydroxy-1-(3-pyridyl)-1- butanone (HPB) and of4-aminobiphenyl (4-ABP) were quantified in blood samples from smokers and nonsmokers to test their suitability for biomonitoring tobacco smoke exposure.Additionally, ThNA adducts were measured in nasal snuff users.Mild alkaline treatment ofhemoglobin releases 4-ABP and HPB, which were analyzed in parallel by capillary gas chromatography with electronic impact or negative ion chemical-ionization mass spectrometry (El-or NICI-GC-MS).Samples ofsnuff users showed high levels ofHPB adducts not correlated with the amount or type ofsnuffused.HPB con- centrations in smokers and nonsmokers, however, were much lower, with no group-specific differences detectable.In contrast, 4-ABP adduct levels were much higher in smokers than in nonsmokers, confirming the significant difference be- tween these two groups reported by others.
Abstract 205: Dysfunction of the 19S Proteosome Contributes to Adverse Cardiac Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor
Authors: Wei Wang, Gabor Szalai, Natarajan Sivasubramanian, Douglas L Mann
Journal: Circulation (2007)

We have shown previously that mice with cardiac restricted overexression of tumor necrosis factor (sTNF mice) develop progressive cardiac remodeling. Given that the ubiquitin/ proteasome system regulates protein turnover in eukaryotic cells and is thereby a major factor in controlling cell cycle, apoptosis, signal transduction pathways, which are important in cardiac remodeling, the purpose of this study was to assess the function of 19S, 20S and 26S proteasome in sTNF mice and littermate control mice. Results : Activity of the 26S proteasome was significantly suppressed in the hearts of the sTNF mice compared with the wild type littermates, and was detectable as early as 4-weeks of age. To explore the mechanism for the dysfunction of the 26S proteosome, we examined the activity of the 19S and 20S subunits. We observed cleavage of two subunits of the 19S regulatory complex of the proteasome, namely S1 and S10b, in the hearts of the sTNF mice. S1 is involved in the linking of the lid and the base of the 19S complex, while S10b is one of the six ATPase subunits in the base of the 19S complex. Interestingly, we observed that the expression of six subunits of the 20S core complex, β2, β2i, β3, β4, β5, and β7 were up-regulated in the hearts of the sTNF mice compared with the wild type littermate control mice. Despite the higher expression of the six β subunits in the 20S complex, we observed no difference in the 20S proteasome activity in hearts between the sTNF mice and the wild type littermate controls. Conclusion : Taken together, these results suggest that cleavage of S1 and S10b might contribute to the low 26S proteasome activity in the hearts of the sTNF mice. Given that the 26S proteasome is responsible for degrading pro-apoptotic pathways, as well as turning off pro-fibrotic signaling (TGF-beta), these results suggest that dysfunction of the 26S proteasome might be one of the mechanisms underlying left ventricular remodeling in the setting of sustained inflammation.
A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants
Journal: New England Journal of Medicine (1985)

Since the murine monoclonal antibody OKT3 reacts with human T cells and blocks their function, we explored its effectiveness in treating T-cell-mediated rejection of renal allografts. In a prospective randomized multicenter trial, 123 patients undergoing acute rejection of cadaveric renal transplants were treated either with OKT3 daily for a mean of 14 days, with concomitant lowering of the dosage of other immunosuppressive drugs (63 patients), or with conventional high-dose steroids (60 patients). OKT3 reversed 94 per cent of the rejections--a figure that was significantly better (P = 0.009) than the 75 per cent reversal rate obtained with conventional steroid treatment. This superior reversal rate with OKT3 was reflected in an improved one-year graft survival of 62 per cent for the OKT3-treated group, as compared with 45 per cent for the steroid-treated group (P = 0.029), in patients who were all selected by virtue of having had acute rejection. We conclude that treatment with OKT3 (with concomitant lowering of the dosage of other immunosuppressive drugs) is an effective approach for acute renal-allograft rejection.
GranatumX: A Community-Engaging, Modularized, and Flexible Webtool for Single-Cell Data Analysis
Authors: David G. Garmire, Xun Zhu, Aravind Mantravadi, Qianhui Huang, Breck Yunits, Yu Liu, Thomas Wolfgruber, Olivier Poirion, Tianying Zhao, Cédric Arisdakessian, Stefan Stanojevic, Lana X. Garmire
Journal: Genomics Proteomics & Bioinformatics (2021)

We present GranatumX, a next-generation software environment for single-cell RNA sequencing (scRNA-seq) data analysis. GranatumX is inspired by the interactive webtool Granatum. GranatumX enables biologists to access the latest scRNA-seq bioinformatics methods in a web-based graphical environment. It also offers software developers the opportunity to rapidly promote their own tools with others in customizable pipelines. The architecture of GranatumX allows for easy inclusion of plugin modules, named Gboxes, which wrap around bioinformatics tools written in various programming languages and on various platforms. GranatumX can be run on the cloud or private servers and generate reproducible results. It is a community-engaging, flexible, and evolving software ecosystem for scRNA-seq analysis, connecting developers with bench scientists. GranatumX is freely accessible at http://garmiregroup.org/granatumx/app.
Immunological Aspects of Experimental and Clinical Cancer
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Immunological Aspects of Experimental and Clinical Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 4, April 1979, Page 1118, https://doi.org/10.1093/jnci/62.4.1118-a Published: 01 April 1979
FRI0261 Tnf Inhibitor Therapy and Risk of Breast Cancer Recurrence in Patients with Rheumatoid Arthritis– A Nationwide Cohort Study
Authors: P. Raaschou, T. Frisell, J. Askling
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Tumor necrosis factor inhibitors (TNFi) have become a mainstay treatment for chronic inflammatory diseases such as Rheumatoid Arthritis (RA). Based on concerns that TNFi might increase the risk of cancer recurrence, in combination with limited evidence, most clinical guidelines advice against the use of this therapy in patients with a history of cancer during the last five or ten years. <h3>Objectives</h3> To investigate the risk of breast cancer recurrence in female patients with RA and a history of breast cancer starting treatment with TNFi, taking RA, breast cancer and comorbidity-related factors into account. <h3>Methods</h3> Nationwide, population-based matched cohort study based on prospectively recorded data in Sweden.120 TNFi-treated (1999-2010) and 120 matched biologics-naïve individuals with RA and a history of equally recent/distant breast cancer were identified through register linkages. Through register linkages and chart review, individuals were followed for first recurrence of breast cancer through 2011. Hazard ratios (HRs) for recurrence were calculated using Cox regression. <h3>Results</h3> The median time from breast cancer diagnosis until TNFi treatment/start of follow-up was 9.4 years. Modest differences in breast cancer characteristics and/or treatment among TNFi-treated and biologics-naive were noted at time of breast cancer diagnosis. Median follow-up was 4.9 years from TNFi start (4.6 years among biologics-naïve). Among the TNFi-treated, 9 developed a breast cancer recurrence (crude incidence rate 15/1000 person-years) during follow-up, compared to 9 among the matched biologics-naïve (16/1000 person-years). The corresponding HR was 0.8 (95% CI 0.3-2.1). Adjusting for the observed differences in breast cancer characteristics, the HR was 1.1 (95% CI 0.4-2.8). The HR for recurrence was 1.4 (95% CI 0.2-8.6) among patients who started TNFi within five years from their breast cancer diagnosis, and 0.8 (95% CI 0.3-2.4) among patients who started TNFi more than five years after their breast cancer. <h3>Conclusions</h3> Among patients with RA and a history of breast cancer, those who started TNFi treatment did not experience more breast cancer recurrences than RA patients treated otherwise. The generalizability of our findings to women with a very recent or a poor prognosis breast cancer remains unknown. <h3>Acknowledgements</h3> We thank Mattias Lundström for assisting in the collection of data <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5011
Obituary
Authors: Herbert D. Kerman
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects
Authors: K Anderson
Journal: Hepatology (1991)

This study compared the effects of diet and cimetidine on theophylline metabolism and examined interactions between these effects. Twelve men received a high-protein diet for 15 days and at another time a high-carbohydrate diet also for 15 days. Cimetidine, 800 mg daily at bedtime, was administered on days 10 through 15 of each dietary period. Theophylline metabolism was studied after the administration of a single intravenous 3 mg/kg dose on days 8 and 15 of each dietary period. Changing from a high-protein to a high-carbohydrate diet decreased theophylline clearance by about the same extent (30% ± 10%) as treatment with cimetidine (37% ± 5% during a high-protein diet and 30% ± 5% during a high-carbohydrate diet). Cimetidine did not significantly influence the effects of diet on theophylline clearance. Conversely, dietary composition did not influence the degree of inhibition of theophylline metabolism induced by cimetidine. Depending on the direction of the change in protein/carbohydrate ratio, the effects of diet and cimetidine treatment were either additive (theophylline clearance was most prolonged during the highcarbohydrate regimen with concurrent cimetidine administration) or counteractive (increasing the dietary protein/carbohydrate ratio at least partially counter-acted the inhibitory effect of cimetidine). In individual subjects, effects of cimetidine on theophylline metabolism were somewhat more consistent than diet-induced changes. The results are further evidence that diet and drugs can have similar effects on hepatic drug metabolism rates in humans. Variations in diet over time and individual differences in responses to diet may provide the potential for considerable instability of drug metabolism rates in free-living subjects. Therefore during treatment with a drug having a narrow therapeutic index, it may be important to consider the potential significance of drug-nutrient interactions and drug-drug interactions in producing subtherapeutic or excessive drug levels. (HEPATOLOGY 1991;13:941–946.)
In 2020
Authors: Beth C. Garbitelli
Journal: Annals of Internal Medicine (2021)

Ad LibitumJune 2021In 2020FREEBeth C. GarbitelliBeth C. GarbitelliTufts University School of Medicine, Boston, MassachusettsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-1407 Audio Reading - “In 2020” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “In 2020” by Beth C. Garbitelli Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail We startedTrying antifungals on our facesSweat and paper turned our skin against usWe baked breadWe watched riotsOur hair on fireOur hands tetheredOur mouths shut and coveredWe feared intimacy togetherIn 2020The pain, the rageOur country built on so much badOur cities burnedIt wasNot a cleansing fireIn 2020I wore perfume to bed“Aromatherapy”It was my litmusTest to seeIf I could still smellThe first theft of the virusI hate many thingsAnd one of themIs the sound a child makesWhen we scrape the back of their noseFor this plagueThey bleed and cry and thrashIn 2020I fell into oceansAnd walked on sandDove into rippled watersPadded my feet with smooth stonesSun-driedI chased my daysAt night, I pitted cherriesThat stained my fingernails redA doctor told meAs a jokeThat I gave a patient a strokeBecause of my powerful handsWhat a burden to feelThat strong. And an illusionIn 2020I fell into the companyOf a young manWho spent his springWilling to bargain for each lifeStubborn and stunnedHe said he watched each patientAs they sat, decompensatingWe call them “happy hypoxics”They looked at televisionsWhile their blood turned blackWe use a toolCalled a bladeIt can cut teethIntubation is an actOf force, almost violenceLike a birthWe make you breatheOr we tryWe are not GodIn 2020 Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Tufts University School of Medicine, Boston, MassachusettsCurrent Author Address: Beth C. Garbitelli; e-mail, elizabeth.[email protected]edu.This article was published at Annals.org on 20 April 2021. PreviousarticleNextarticle Advertisement Audio Reading - “In 2020” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “In 2020” by Beth C. Garbitelli Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics June 2021Volume 174, Issue 6Page: 871 ePublished: 20 April 2021 Issue Published: June 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Hypothermia: Effects Upon Hematologic Clearance in Experimentally Staphylococcic Bacteremia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Curare-Like Activity of Polypropylene Glycol Adducts-L. P. McCarthy and M. B. Chenoweth
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Osleriana
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal